- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02764892
A Study in Healthy Male Volunteers to Investigate a New Drug for the Treatment of Parkinson's Disease
An Open Label Study of V81444 Using Positron Emission Tomography to Assess Occupancy of Brain Adenosine A2A Receptors & Functional & Perfusion MRI to Explore Effects on Regional Brain Activity & Perfusion in Healthy Male Volunteers
Study Overview
Detailed Description
In this Phase I, single-centre, open-label, adaptive, single-dose study at multiple dose levels, the relationship between dose and plasma concentration of orally administered V81444 to brain A2A RO was investigated in 6 healthy male volunteers. In addition, the effects of V81444 on regional brain activity and perfusion during tests of cognitive function, and the safety and tolerability of V81444 were assessed. For each subject, the study consisted of a screening visit, a baseline visit, a treatment period, and a safety follow-up visit. The dose of V81444 and timing of scans performed were defined in the protocol for the first 2 subjects only. The dose, nature and timings of assessments for subsequent subjects were determined based on review of emerging receptor binding, pharmacokinetic (PK), pharmacodynamic (PD) and safety information.
In each treatment period, subjects were admitted to the unit on the day before dosing (Day -1), received a single oral dose of V81444 on Day 1 and, subject to satisfactory medical review, were discharged a minimum of 12 h after dosing. Overall, 3 doses of V81444 were assessed (250 mg, 50 mg, and 100 mg), with 2 subjects included at each dose level. PD assessments were performed at baseline and after each dose of V81444 using PET (with the A2A radioligand, to measure brain A2A RO, as well as MRI techniques to investigate the effects of V81444 on regional brain activity and perfusion during cognitive function tests. PK parameters were assessed by assay of V81444 concentration in plasma. Safety and tolerability were assessed by monitoring physical examination findings, adverse events (AEs), vital signs, 12 lead electrocardiogram (ECG) and clinical laboratory safety tests.
Study Type
Enrollment (Actual)
Phase
- Phase 1
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Healthy male volunteers: aged 25 to 55 years, in good general health as determined by medical history, physical examination and screening investigations, and taking no regular medication.
- Confirmation to be sought for all volunteers that their general practitioner has provided an acceptable medical history.
Exclusion Criteria:
- Any significant medical condition or a history of such a condition that the Investigator considers should exclude the subject from the study.
Specific exclusion criteria relate to
- usual caffeine intake and willingness to abstain from caffeine
- history or evidence of clinically significant gastro-intestinal disease
- presence of structural brain abnormality
- contraindications or cautions for MRI scanning
- clotting test results
- exposure to significant levels of ionising radiation in the past
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: V81444
Single oral dose of V81444
|
Single oral dose of V81444
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Plasma concentration V81444 corresponding with 50% brain A2A receptor occupancy.
Time Frame: Up to 27 hours after a single dose
|
Plasma concentrations of V81444 and binding of [11C]SCH442416 radioligand to brain A2A receptors using PET before and after V81444 dosing to determine occupancy of A2A receptors by V81444.
|
Up to 27 hours after a single dose
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Cognitive function using functional MRI
Time Frame: 5 hours after dosing
|
5 hours after dosing
|
Change versus placebo in proportion of subjects with adverse events
Time Frame: Up to 7 Days after last dose
|
Up to 7 Days after last dose
|
Change versus placebo in proportion of subjects with abnormal laboratory findings
Time Frame: Up to 7 Days after last dose
|
Up to 7 Days after last dose
|
Change versus placebo in proportion of subjects with clinically significant abnormalities on vital signs
Time Frame: Up to 7 Days after last dose
|
Up to 7 Days after last dose
|
Change versus placebo in proportion of subjects with clinically significant abnormalities in 12-lead ECG
Time Frame: Up to 7 Days after last dose
|
Up to 7 Days after last dose
|
Change versus placebo in proportion of subjects with clinically significant abnormalities on physical examination
Time Frame: Up to 7 Days after last dose
|
Up to 7 Days after last dose
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- V81444-1PD-02
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Parkinson's Disease
-
Ohio State UniversityCompletedParkinson's Disease | Parkinson Disease | Idiopathic Parkinson Disease | Idiopathic Parkinson's Disease | Parkinson Disease, Idiopathic | Parkinson's Disease, IdiopathicUnited States
-
Assistance Publique - Hôpitaux de ParisFrance Parkinson AssociationUnknownHealthy Controls | Parkinson's Disease With LRRK2 Mutation | Parkinson's Disease Without LRRK2 MutationFrance
-
Merck Sharp & Dohme LLCCompletedParkinson Disease | Idiopathic Parkinson Disease | Idiopathic Parkinson's Disease
-
Universidade Federal de PernambucoCompletedParkinson's Disease.Brazil
-
University Hospital, GrenobleCompletedParkinson's Disease (Disorder)France
-
Neurocrine BiosciencesVoyager TherapeuticsCompletedBrain Diseases | Central Nervous System Diseases | Nervous System Diseases | Parkinson's Disease | Parkinsonian Disorders | Movement Disorders | Neurodegenerative Diseases | Idiopathic Parkinson's Disease | Basal Ganglia DiseaseUnited States
-
Second Affiliated Hospital of Soochow UniversityShanghai Regenelead Therapies Co., Ltd.RecruitingAdvanced Parkinson's DiseaseChina
-
AbbVieRecruitingParkinson's Disease (PD)Germany, Denmark, Spain
-
Beijing Tiantan HospitalRecruitingPD - Parkinson's DiseaseChina
-
Hubert FernandezRecruitingParkinson's Disease, IdiopathicUnited States
Clinical Trials on V81444
-
Vernalis (R&D) LtdCompletedParkinson's DiseaseUnited Kingdom
-
Vernalis (R&D) LtdCompleted